1 December 2016 - Arsanis today announced that the U.S. FDA has granted fast track designation to ASN100 for the prevention of Staphylococcus aureus pneumonia in mechanically ventilated patients who are at high risk for S. aureus pneumonia.

“Despite current antibiotic treatments, S. aureus pneumonia has a mortality rate as high as 30 percent in this patient population1,” said René Russo, Pharm.D., BCPS, Chief Executive Officer, Arsanis. “We are pleased that the FDA has granted Fast Track designation to ASN100 to prevent S. aureus pneumonia in high-risk, mechanically ventilated patients, and we look forward to working closely with the Agency as we continue the development of our lead monoclonal antibody program for this vulnerable patient population.”

Read Arsanis press release